Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The War on Generics - Part II

This article was originally published in RPM Report

Executive Summary

Teva says it isn't worried about the more aggressive pricing strategies used by brand companies to blunt blockbuster generic launches. What if the world's largest generic company is wrong? Part II of this two-part series looks at the future of the generic drug industry.

Related Content

FTC Study of Authorized Generics Gets Off the Ground: Now What?
Betting Generic: Part D, Patents and Proteins Drive Investment Surge
Reinventing Pharmacy: The Bidding for Caremark is Just the Beginning
Reinventing Pharmacy: The Price Increase for Caremark Could Be a Price Decrease for Manufacturers
Generic Plavix: As Bristol Swoons, Broad Implications
The War on Generics - Part I
Generics Attract Royalty Funding Options Too
Mylan's War on Authorized Generics
Generics in Italy: Angelini's Positioning Play
Generic Update: Brand-Name Companies Vs. Independents


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts